Anemia in myelofibrosis significantly affects survival and quality of life, with severe anemia reducing median survival ...

Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well, the first step is diagnosis. We have ...

Please provide your email address to receive an email when new articles are posted on . Patients with chronic kidney disease and their care partners report a considerable burden, especially when the ...

The use of ESAs should be discouraged in cancer patients who are not undergoing treatment with chemotherapy or radiotherapy. This recommendation is based primarily on a large, randomized, Phase III, ...

In a study, end-stage renal disease was 31% more likely to develop in CKD patients with versus without anemia. NEW ORLEANS—Anemia is independently associated with an increased risk for end-stage renal ...

A 56-year-old man was admitted to the hospital because of left lower abdominal pain and anemia. He had a 1-year history of ...

A local sickle cell anemia patient met some of his blood donors who helped him get life-saving treatment. The donors-recipient meeting was held at the Rhode Island Blood Center’s Warwick Donor Center ...

Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting. Improvements in thrombocytopenia and anemia were observed in patients with ...

Anemia is a common finding in patients with diabetes due to the high burden of chronic kidney disease in this population. Anemia is more prevalent and is found earlier in patients with diabetes than ...

Table 2. Recommendations for the use of erythropoiesis-stimulating agents in patients with nonhematological malignancies. Organization Anemia related to chemotherapy Untreated patients Patients ...